1.Generation and characterization of monoclonal antibodies against chicken interleukin 4.
Xiaoyu GUAN ; Zhichao XU ; Yongqiang WANG ; Xiaoqi LI ; Hong CAO ; Shijun ZHENG
Chinese Journal of Biotechnology 2017;33(1):44-54
To develop monoclonal antibodies (McAbs) against chicken interleukin 4 (chIL-4), we subcloned the mature chIL-4 gene into prokaryotic expression vectors pET-28a and pGEX-6P-1, then expressed and purified the recombinant proteins. We immunized BALB/c mice with the purified His-chIL-4 protein and fused the murine splenocytes with SP2/0 after 4 times of immunization. We used the GST-chIL-4 protein as a coating antigen to establish an indirect ELISA to screen positive clones. After screening and 3 rounds of cloning process, we obtained 3 hybridomas that stably secreted McAbs against chIL-4, and named 1G11-3B, 2E5-3D, and 1G11-5H. The isotypes of these McAbs were all IgG1 and the dissociation constant (Kd) of these McAbs were 1.79×10⁻⁹, 1.61×10⁻⁹, and 2.36×10⁻⁹, respectively. These McAbs specifically bound to chIL-4 expressed by either prokaryotic or eukaryotic system as determined by Western blotting and indirect immunofluorescence assay. The binding domains of chIL-4 recognized by 1G11-3B, 2E5-3D, and 1G11-5H were located between aa 1-40, 80-112, and 40-80, respectively, as determined by Western blotting. These McAbs would help to detect chIL-4 and to elucidate the biological roles of chIL-4 in immune responses.
2.Value of serum IgA/C3 ratio in the diagnosis of IgA nephropathy and its correlation with the clinicopathological features.
Shuangshuang ZHU ; Yongqiang LI ; Shulu ZHOU ; Qingzhu WEI ; Kangping DENG ; Xiaohong WANG ; Bin LI ; Jianghuan LIU ; Xinyu LIU ; Ying ZHANG ; Xiaofei SHAO ; Aiqun LIU ; Bifang WU ; Zhihong ZHAO ; Xiaomeng XU ; Hanfei LIN ; Qin LIU ; Jiamin LI ; Honglei WANG ; Qin ZHOU ; Chaoya ZHU ; Daoyuan LV ; Yue XIA ; Hequn ZOU
Journal of Southern Medical University 2015;35(12):1683-1688
OBJECTIVETo investigate the value of serum IgA/C3 ratio in the diagnosis of IgA nephropathy and explore its relationship with the clinicopathological features of the patients.
METHODSSixty-six patients with IgA nephropathy, 111 with other glomerular diseases, and 40 healthy control subjects without kidney disease were tested for serum IgA and C3 levels using CRM470 adjusted standardized immune turbidimetric method, and the IgA/C3 ratio was calculated. According to Oxford and Lee's classification criteria, we analyzed the pathological grades of the renal biopsy samples from patients with IgA nephropathy. The ROC curve was used to assess the value of serum IgA and IgA/C3 ratio in predicting IgA nephropathy.
RESULTSPatients with IgA nephropathy had an elevated serum IgA/C3 ratio than those with other glomerular diseases and the control subjects, with an area under the ROC curve of 0.776. An elevated serum IgA/C3 ratio was not found to significantly correlate with the pathological grade of renal biopsy samples in patients with IgA nephropathy.
CONCLUSIONIn the absence of renal biopsy findings, serum IgA/C3 ratio can help in the diagnosis of IgA nephropathy.
Biopsy ; Case-Control Studies ; Complement C3 ; analysis ; Glomerulonephritis, IGA ; blood ; diagnosis ; Humans ; Immunoglobulin A ; blood ; Kidney ; pathology
3.Study on the regulatory effects of mechano growth factor on soft tissue repair.
Can YU ; Yongqiang SHA ; Pan GUO ; Yimei CHEN ; Lucy Wanjiru NJUNGE ; Yonggang LU ; Li YANG
Journal of Biomedical Engineering 2015;32(1):235-239
Mechano growth factor (MGF) is an autocrine/paracrine factor and sensitive to mechanical stimulation. MGF can be highly expressed in various soft tissues under physical stimuli, biochemistry stimuli or in damaged situation. MGF may "compensate" the stress for tissue in the processing of tissue repair. MGF can effectively accelerate the repair of the soft tissue by promoting the proliferation, migration and differentiation of cells. This paper summarizes the MGF expressions in different soft tissues and their functions in soft tissue repair. The paper also discusses current problems and challenges in using MGF to repair the soft tissue.
Cell Differentiation
;
Cell Proliferation
;
Humans
;
Insulin-Like Growth Factor I
;
physiology
;
Soft Tissue Injuries
;
Wound Healing
4.Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial.
Xiaoyan GE ; Linhua YANG ; Jie JIN ; Wenbin QIAN ; Jianyong LI ; Renchi YANG ; Xiangshan CAO ; Bin JIANG ; Zhao WANG ; Ming HOU ; Weihua ZHANG ; Zhongping XIAO ; Yongqiang ZHAO ; Da GAO ; Xiaohong ZHANG ; Shuye WANG ; Aining SUN ; Jinxiang FU ; Li SU ; Kang LI
Chinese Journal of Hematology 2015;36(7):547-552
OBJECTIVETo evaluate the efficacy and safety of anagrelide in essential thrombocythemia (ET).
METHODSPatients who diagnosed as ET according to the World Health Organization classification were enrolled. Each patient was assigned to take anagrelide hydrochloride capsule or hydroxyurea tablet by random 1∶1 ratio. Dose of anagrelide started at 2 mg/d, then increased gradually and the maximum dose was 10 mg/d until the platelet counts dropped to (100-400) × 10⁹/L, one month later gradually reduced to maintain dose. The dose of hydroxyurea was 1000 mg/d at beginning, then increased gradually, when platelet counts dropped to (100-400)×10⁹/L and kept for one month, reduced to maintain dose as 10 mg·kg⁻¹·d⁻¹. The observation period was 12 weeks.
RESULTSA total of 222 patients were enrolled in seventeen centers (including 113 patients treated with anagrelide and 109 with hydroxyurea). Therapy efficacy can be evaluated in 198 patients (including 97 patients administered with anagrelide and 101 with hydroxyurea). At 12th weeks of therapy, the hematologic remission rate was 87.63% (85/97) in anagrelide group and 88.12% (89/107) in hydroxyurea group, the differences between the two groups were not significant (P=0.173). Treatment with anagrelide lowered the platelet counts by a median of 393 (362-1 339) × 10⁹/L from a median of 827 (562-1657) × 109/L at the beginning of the observation to 400(127-1130)×10⁹/L after 12 weeks (P<0.001), which were similar to the treatment result of hydroxyurea by a median drop of 398 (597-1846)× 10⁹/L (P=0.982). The median time to achieving response of anagrelide group was 7 (3-14) days, superior to that of hydroxyurea for 21 (14-28) significantly (P=0.003). Frequency of anagrelide related adverse events was 65.49 % (74/113), including cardiopalmus (36.28% ), headache (21.24% ), fatigue (14.16% ) and dizzy (11.50% ).
CONCLUSIONAnagrelide was effective in patients with ET which had similar hematologic remission rate to hydroxyurea and could take effect more quickly than hydroxyurea. Incidence of adverse events was undifferentiated between anagrelide and hydroxyurea, but anagrelide treatment had tolerable adverse effects and no hematologic toxicity.
Humans ; Hydroxyurea ; administration & dosage ; therapeutic use ; Platelet Aggregation Inhibitors ; administration & dosage ; therapeutic use ; Platelet Count ; Quinazolines ; administration & dosage ; therapeutic use ; Thrombocythemia, Essential ; drug therapy ; Treatment Outcome
5.Development and Application of the Reverse Genetic Technologies for Infectious Bursal Disease Virus.
Xiaole QI ; Yongqiang WANG ; Li GAO ; Honglei GAO ; Yulong GAO ; Xiaomei WANG
Chinese Journal of Virology 2015;31(3):326-331
Infectious bursal disease virus (IBDV) is an important member of the Birnaviridae family. IBUV mainly targets the bursa of Fabricius, the central immune organ of chicken, resulting in chicken infectious bursal disease (IBD). IBD represents one of the great challenges for ongoing development of the poultry industry. Reverse genetics for IBDV emerged over twenty years ago. Since then, the technologies behind virus rescue have continually improved leading to a deep understanding of IBDV gene function and tailored vaccine development. Our lab has also been instrumental in the field of IBDV research. Here we review studies on the pathogenic mechanism and the effective prevention and control of IBD.
Animals
;
Birnaviridae Infections
;
virology
;
Chickens
;
Infectious bursal disease virus
;
genetics
;
physiology
;
Poultry Products
;
virology
;
Reverse Genetics
6.Development of monoclonal antibodies against the gp90 protein of reticuloendotheliosis virus and mapping of their recognition regions.
Mingming SUN ; Xiaoqi LI ; Hong CAO ; Yongqiang WANG ; Shijun J ZHENG
Chinese Journal of Biotechnology 2015;31(1):75-85
In order to develop monoclonal antibodies (McAbs) against the gp90 protein of reticuloendotheliosis virus (REV), the His-tagged gp90 protein of REV was used to immunize BALB/c mice. Hybridomas were generated by fusing mouse myeloma cells SP2/0 with the splenocytes from the immunized mice. After screening and 3 rounds of cloning process, 3 hybridomas (3G5-B8, 3G5-A10 and 1G12) that stably secreted McAbs against the REV-gp90 were obtained. The isotypes of the McAbs were determined to be IgG1, IgG1 and IgG2b. The McAbs specifically bound to gp90 in REV-infected DF-1 cells, as demonstrated by Western blotting and indirect immunofluorescence assay. The recognition regions on gp90 that were recognized by 3G5-B8/3G5-A10 and 1G12 were located between amino acids 200 to 245 and 230 to 235, respectively, as demonstrated by Western blotting analysis. These McAbs will be useful in the diagnosis and pathogenesis study of REV.
Animals
;
Antibodies, Monoclonal
;
biosynthesis
;
Antibody Specificity
;
Blotting, Western
;
Epitope Mapping
;
Hybridomas
;
Immunoglobulin G
;
biosynthesis
;
Mice
;
Mice, Inbred BALB C
;
Reticuloendotheliosis virus
;
immunology
;
Viral Envelope Proteins
;
immunology
7.Effect of intermediate-dose cytarabine on mobilization of peripheral blood hematopoietic stem cell in acute myeloid leukemia.
Muchen XIE ; Yu ZHANG ; Min DAI ; Qi WEI ; Xiaofang LI ; Yongqiang WEI ; Fen HUANG ; Zhiping FAN ; Qianli JIANG ; Qifa LIU ; Jing SUN ; Ru FENG
Chinese Journal of Hematology 2014;35(7):587-591
OBJECTIVETo explore the impact of courses of intermediate-dose cytarabine (ID-Ara-C) chemotherapy on the efficiency of hematopoietic stem cell mobilization in acute myeloid leukemia (AML) patients with autologous hematopoietic stem cell transplantation (auto-HSCT).
METHODS90 patients with de novo AML undergoing auto-HSCT between August 1999 and November 2012 were enrolled. All patients received the mobilization regimen of cytarabine and etoposide chemotherapy in combination with recombinant human granulocyte-colony stimulating factor (rhG-CSF). Stem cell apheresis was scheduled when blood leukocyte count recovered greater than 4.0 × 10⁹/L or the proportion of CD34⁺ cells greater than 1% in peripheral blood. The impact of ID-Ara-C courses on the mobilization efficiency was analyzed retrospectively.
RESULTSAccording to the ID-Ara-C courses, patients were divided into group A (<2 courses), B (2 courses), and C (>2 courses). The median doses of CD34⁺ cells (×10⁶/kg) in three groups were 4.7, 2.7, 2.3, respectively (P=0.003). Of the available 87 patients who could be evaluated, 61 (70.1%) cases had CD34⁺ cells greater than 2.0 × 10⁶/kg, and 26 (29.9%) cases less than 2.0 × 10⁶/kg. Of the 26 patients without satisfactory mobilization efficiency, 7 (15.2%) were in group A, 10 (47.6%) in group B, and 9 (45.0%) in group C (χ²=10.05, P=0.007). In addition, patients with satisfactory mobilization efficiency (CD34⁺ cells ≥ 2.0×10⁶/kg) in groups C needed more times of collection, more volume of blood processed, and even high-dose and longer course of rhG-CSF (P<0.05). In univariate analysis. The ID-Ara-C courses and the cumulative dose were significant correlate with mobilization efficiency. In multivariate analysis, the ID-Ara-C courses was an independent correlation factor for mobilization efficiency (odd ratio=0.623, 95% confidence interval=0.418-0.926, P=0.019). The sex, age, cytogenetic risk, the standard chemotherapy courses did not correlate with mobilization efficiency.
CONCLUSIONThe number of ID-Ara-C courses was independent factor for the mobilization efficiency and should be taken seriously in AML patients with auto-HSCT.
Adolescent ; Adult ; Child ; Cytarabine ; administration & dosage ; therapeutic use ; Female ; Hematopoietic Stem Cell Mobilization ; Humans ; Leukemia, Myeloid, Acute ; drug therapy ; Male ; Middle Aged ; Peripheral Blood Stem Cell Transplantation ; Retrospective Studies ; Treatment Outcome ; Young Adult
8.The prevalence of Acinetobacter baumannii in hematology ward of single center from 2010 to 2012.
Lu WANG ; Qian ZHANG ; Bing HAN ; Junling ZHUANG ; Miao CHEN ; Nong ZOU ; Jian LI ; Minghui DUAN ; Wei ZHANG ; Tienan ZHU ; Ying XU ; Shujie WANG ; Daobin ZHOU ; Yongqiang ZHAO ; Hui ZHANG ; Peng WANG ; Yingchun XU
Chinese Journal of Hematology 2014;35(3):239-241
Acinetobacter Infections
;
epidemiology
;
microbiology
;
Acinetobacter baumannii
;
isolation & purification
;
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Cross Infection
;
epidemiology
;
microbiology
;
Female
;
Hematologic Diseases
;
microbiology
;
Hospital Units
;
Humans
;
Male
;
Middle Aged
;
Prevalence
;
Young Adult
10.Noninvasive imaging evaluation of aortico-left ventricular tunnel: a case report.
Xiaohu LI ; Ren ZHAO ; Bin LIU ; Wanqin WANG ; Yongqiang YU ; Xuegong SHI ; Yan XU
Chinese Journal of Cardiology 2014;42(4):345-346
Aorta
;
abnormalities
;
Child
;
Heart Defects, Congenital
;
diagnosis
;
Heart Ventricles
;
abnormalities
;
Humans
;
Male

Result Analysis
Print
Save
E-mail